Monitor the full ASCO poster on May 30 for additional efficacy details and dose expansion data. Positive early signals could support partnership interest or pipeline valuation, but the small sample size warrants caution until larger cohorts confirm.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $13.68entry
- T+1 · 6mo ago −0.95%α −1.54% · $13.55
- T+5 · 6mo ago −7.09%α −8.75% · $12.71
- T+20 · 5mo ago −25.51%α −24.10% · $10.19
- T+60 · 3mo ago −22.15%α −25.34% · $10.65
Price Chart
How similar events traded
Executive Summary
Olema Pharmaceuticals announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability, target engagement, and early anti-tumor activity (3 partial responses in 19 evaluable patients) in heavily pretreated advanced solid tumors. The data will be presented at ASCO 2026 on May 30. This early clinical signal supports continued development but remains preliminary.
Key Facts
- No dose-limiting toxicities observed up to 45 mg daily; no treatment discontinuations due to TRAEs.
- Among 19 evaluable patients, tumor shrinkage in 13, with 2 confirmed and 1 unconfirmed partial response.
- OP-3136 demonstrated sustained reduction in H3K23 acetylation, confirming on-target KAT6 inhibition.
- Data to be presented at ASCO 2026 (May 30) and Phase 1 dose expansion ongoing.
- The company also will present a trial-in-progress for Phase 3 OPERA-02 (palazestrant + ribociclib) at ASCO.
Financial Impact
No financial figures disclosed; early clinical data may increase probability of success for OP-3136 pipeline value.
Risk Factors
- Phase 1 data is preliminary with small sample size (19 evaluable); response rates may not be durable or reproducible in larger groups.
- Common grade 3 TRAEs (anemia 6%, neutropenia 28%) may limit tolerability at higher doses or in combination.
- No control arm; efficacy signals need confirmation in randomized expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-234848 |
| Document: olma-ex99_1.htm | 0001193125-26-234848 |
| Document: 0001193125-26-234848-index-headers.html | 0001193125-26-234848 |
| Document: 0001193125-26-234848-index.html | 0001193125-26-234848 |
| Document: 0001193125-26-234848.txt | 0001193125-26-234848 |
Track record
20 reports on OLMA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers